Adocia Logo

Adocia

Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.

ADOC | PA

Overview

Corporate Details

ISIN(s):
FR0011184241 (+1 more)
LEI:
969500ZL79KYH9PTYP78
Country:
France
Address:
115 AVENUE LACASSAGNE, 69003 LYON
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Adocia is a clinical-stage biotechnology company founded in 2005, specializing in the development of innovative treatments for metabolic diseases, primarily diabetes and obesity. The company's core focus is on creating novel formulations of already-approved therapeutic proteins, peptides, and hormones, such as insulin, to improve their performance. Its diverse pipeline targets type 1 and type 2 diabetes and obesity. Additionally, Adocia develops platforms for cell therapies, including immunoprotective scaffolds. The company's business model is to develop products and technologies to the human proof-of-concept stage before licensing them to commercial partners.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-02 10:34
Major Shareholding Notification
Déclaration d'intention (FS 225C1435)
French 130.2 KB
2025-09-02 10:30
Major Shareholding Notification
Franchissement de seuil
French 111.8 KB
2025-07-11 11:18
Major Shareholding Notification
Franchissements de seuil
French 116.2 KB
2025-06-12 18:00
Declaration of Voting Results & Voting Rights Announcements
Inside Information / Other news releases
English 492.1 KB
2025-06-12 18:00
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 491.7 KB
2025-05-22 18:00
Regulatory News Service
Inside Information / Other news releases
English 452.1 KB
2025-05-22 18:00
Regulatory News Service
Informations privilégiées / Autres communiqués
French 472.2 KB
2025-05-21 18:00
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 120.9 KB
2025-05-21 18:00
Pre-Annual General Meeting Information
Inside Information / Other news releases
English 130.5 KB
2025-05-15 18:00
Declaration of Voting Results & Voting Rights Announcements
Inside Information / Other news releases
English 474.1 KB
2025-05-15 18:00
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 473.1 KB
2025-05-14 18:00
Earnings Release
Inside Information / News release on accounts, results
English 576.9 KB
2025-05-14 18:00
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 531.5 KB
2025-04-30 18:00
Registration Form
Inside Information / Other news releases
English 473.1 KB
2025-04-30 18:00
Registration Form
Informations privilégiées / Autres communiqués
French 461.0 KB

Automate Your Workflow. Get a real-time feed of all Adocia filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Adocia

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Adocia via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-03-21 N/A Other Buy 51,921 499,999.23 EUR
2024-03-21 N/A Other Buy 15,576 149,996.88 EUR
2023-12-29 N/A Other Sell 20,000 236,550.00 EUR
2023-10-05 N/A Other Sell 50,000 400,000.00 EUR
2023-09-20 N/A Other Sell 36,240 291,376.85 EUR
2023-07-28 N/A Other Buy 220,264 999,998.56 EUR
2023-07-28 N/A Other Buy 110 499.40 EUR

Peer Companies

Company Country Ticker View
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway NYKD
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland OCS
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea 244460
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea 382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea 476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan 4564
Onxeo Logo
Developing precision-guided therapeutics using small antibodies for complex diseases.
France ALONX
Openedges Technology, Inc. Logo
Semiconductor IP provider of memory subsystem & AI platform IP for AI, HPC, and IoT SoCs.
South Korea 394280
Openjobmetis Logo
Employment agency providing staffing, recruitment, and HR services to companies and job seekers.
Italy OJM
Open Up Group Inc. Logo
Provides staffing and outsourcing of engineers for global manufacturing, IT, and construction sectors.
Japan 2154

Talk to a Data Expert

Have a question? We'll get back to you promptly.